Article info
PDFOriginal research
Unethical informed consent caused by overlooking poorly measured nocebo effects
- Correspondence to Dr Jeremy Howick, Faculty of Philosophy, University of Oxford, Oxford OX2 6GG, UK; jeremy.howick{at}philosophy.ox.ac.uk
Citation
Unethical informed consent caused by overlooking poorly measured nocebo effects
Publication history
- Received October 23, 2019
- Revised January 4, 2020
- Accepted January 13, 2020
- First published February 16, 2020.
Online issue publication
August 23, 2021
Article Versions
- Previous version (16 February 2020).
- Previous version (19 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
- Sharing online clinical notes with patients: implications for nocebo effects and health equity
- PO104 Placebo and nocebo responses in rls: a meta-analysis
- Informed consent and clinical trials: where is the placebo effect?
- Placebo effects and the molecular biological components involved
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Open-label placebo clinical trials: is it the rationale, the interaction or the pill?
- What trial participants need to be told about placebo effects to give informed consent: a survey to establish existing knowledge among patients with back pain
- DTB Select: 5 | May 2013
- Open notes in patient care: confining deceptive placebos to the past?